This is a preview of subscription content, log in via an institution to check access.
Reference
Kampa-Schittenhelm KM, et al. Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFbeta-MYH11 leukemia. Oncotarget 9: 11876-11882, No. 14, 20 Feb 2018. Available from: URL: http://doi.org/10.18632/oncotarget.24376 - Germany
Rights and permissions
About this article
Cite this article
Dasatinib. Reactions Weekly 1694, 157 (2018). https://doi.org/10.1007/s40278-018-43558-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-43558-5